Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00008385 · ClinicalTrials.gov registry record · Phase 3
Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer
A Phase 3 study, sponsored by ECOG-ACRIN Cancer Research Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,772
- Enrollment target
NCT00008385: Completed Phase 3 study, sponsored by ECOG-ACRIN Cancer Research Group.
NCT00008385 is a Phase 3 study that has completed, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 1,772 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (130% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00008385, a Phase 3 study, has completed, sponsored by ECOG-ACRIN Cancer Research Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,772 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known if selenium is effective in preventing the growth of new tumors in patients with previously resected non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying selenium to see how well it works compared to a placebo in preventing the development of second primary lung tumors in patients who have undergone surgery to remove stage I non-small cell lung cancer.
Primary Outcome
Incidence rate of second primary lung tumor was defined as the number of new second primary lung tumors per 100 population at risk in a year.
Interventions
- OTHER placebo
- DRUG selenium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,772 participants |
| Start Date | 2000-12-18 |
| Est. Completion | 2019-11 |
| Phase | Phase 3 |
What the finished NCT00008385 record still lists
NCT00008385 is an interventional study that assigns participants to a tested intervention. Its 1,772 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (130% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00008385 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00008385 about?
NCT00008385 is a clinical study titled "Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known if selenium is effective in preventing the growth of new tumors in patients with previously resected non-small cell lung cancer. PURPOSE: This randomized pha...
What is the current status of trial NCT00008385?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,772 participants. The study started on 2000-12-18. Estimated completion is 2019-11.
What interventions are being tested in trial NCT00008385?
The interventions under investigation include: placebo (OTHER), selenium (DRUG).
Who is sponsoring clinical trial NCT00008385?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00008385's enrollment target sits among peer trials
1,772 126th of 2000 higher than 1,875 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03067181 · 1,780 participants · Phase 3
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
- NCT06526650 · 1,780 participants · NA
'Ai Pono Cooking Demonstrations
- NCT06239688 · 1,764 participants · NA
Evaluating a National Person-Centered Training Program to Strengthen the Dementia Care Workforce
- NCT05770570 · 1,785 participants · Phase 2
Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI